Importantly, clinical data from patients with cancer that do not respond to anti-PD-1 therapy show retinol metabolism as the most enriched pathway,43 while other studies show that ALDH1A3 is often enriched in patients that do not respond to immune checkpoint inhibitors.44 Here, ALDH1A3 is linked to cancer.